Charles River Laboratories International, INC Form 4 insider transactions

Director Martin MacKay of Charles River Laboratories International, Inc. reported the acquisition of 1,438 and 1,407 shares of common stock on May 8, 2026, at a price of $177.62 per share.

Nancy C. Andrews, a Director at Charles River Laboratories International, Inc., reported a transaction involving the acquisition of common stock.

George Llado Sr., a Director at Charles River Laboratories, reported the acquisition of 1,438 common shares and 450 restricted stock units.

Reshema Kemps-Polanco, a Director at Charles River Laboratories, reported the acquisition of 1,973 shares of common stock on May 8, 2026.

Virginia M. Wilson, a Director at Charles River Laboratories International, Inc., reported a transaction involving the acquisition of common stock.

Director James C. Foster of Charles River Laboratories International, Inc. reported the acquisition of 1,438 and 422 shares of common stock on May 8, 2026, at a price of $177.62 per share.

Glenn Coleman, EVP & Chief Financial Officer of Charles River Laboratories International, Inc., reported a transaction involving the disposition of 21,112 shares of common stock.

Charles River Laboratories' Corporate Executive VP & COO, Birgit Girshick, reported gifting 328 shares of common stock and reclassifying other holdings.

Charles River Laboratories CEO James C. Foster acquired 16,796 shares of common stock and updated his beneficial ownership.

Charles River Laboratories EVP Joseph W. LaPlume reported a planned future purchase of 25 shares of common stock at $174.54 per share under a 10b5-1 plan.

Joseph W. LaPlume, EVP of Corporate Strategy & Development at Charles River Laboratories, acquired shares from vested performance units and disposed of a portion for tax obligations.

Victoria L. Creamer, EVP & Chief People Officer at Charles River Laboratories, reported the acquisition of 5,006 shares and the disposition of 1,296 shares of common stock.

Charles River Laboratories CEO James C. Foster acquired 39,031 shares of common stock through performance awards and disposed of 14,664 shares for tax obligations.

Charles River Laboratories' COO, Birgit Girshick, acquired 9,500 shares through performance awards and transferred 45,470 shares to a revocable trust.

Charles River Laboratories' CSVP, CAO, and Interim CFO Michael Knell reported the acquisition of 1,668 shares and disposition of 526 shares of common stock.

Mark Mintz, EVP and Chief Information Officer at Charles River Laboratories, acquired 1,797 shares of common stock through performance-based awards and subsequently disposed of 655 shares for tax purposes.

A Charles River Laboratories executive reported the acquisition of shares from performance awards and subsequent tax-related dispositions and trust transfers.

Charles River Laboratories EVP Joseph W. LaPlume sold 400 shares of common stock for $163.72 per share, a transaction executed under a Rule 10b5-1 plan.

Charles River Laboratories' CSVP, CAO, and Interim CFO, Michael G. Knell, acquired 2,926 shares of common stock through a restricted stock unit grant.

Joseph W. LaPlume, EVP of Corporate Strategy & Development at Charles River Laboratories, reported a planned sale of 800 common shares for August 2025.

Charles River Laboratories EVP Joseph W. LaPlume filed a Form 4 indicating a pre-planned sale of 400 common shares on August 7, 2025, at $150.04 per share.

Joseph W. LaPlume, EVP of Corporate Strategy & Development at Charles River Laboratories, reported gifting 385 shares of common stock, retaining a substantial beneficial ownership of 25,316 shares.

Abraham Ceesay, a Director at Charles River Laboratories International, Inc., acquired 946 shares of common stock and 2,082 stock options on June 2, 2025, as part of a pre-arranged Rule 10b5-1 plan.

Mark J. Enyedy, a Director at Charles River Laboratories International, Inc., acquired 946 shares of common stock and 2,082 stock options on June 2, 2025, as part of a compensation grant.

Paul W. Graves, a Director at Charles River Laboratories International, Inc. (CRL), acquired 946 shares of common stock and 2,082 stock options on June 2, 2025, as part of his compensation, totaling an acquisition value of approximately $408,900 based on the transaction price.

Charles River Laboratories International, Inc. Director Steven Barg reported the acquisition of common stock and stock options through equity grants, including restricted stock units in lieu of director fees, as part of a pre-arranged Rule 10b5-1 plan.

Charles River Laboratories' Corporate Executive VP & CFO, Flavia Pease, reported the acquisition of 7,152 restricted stock units and a subsequent disposition of 185 shares for tax withholding purposes.

A Charles River Laboratories executive, Shannon M. Parisotto, reported the acquisition of 5,603 restricted stock units and a subsequent disposition of 105 shares for tax withholding purposes.

Joseph W. LaPlume, EVP of Corporate Strategy & Development at Charles River Laboratories, reported the acquisition of restricted stock units and a subsequent disposition for tax purposes.

Michael G. Knell, CSVP & Chief Accounting Officer at Charles River Laboratories, reported the acquisition of 2,064 shares of common stock, increasing his beneficial ownership to 10,534 shares after tax-related disposals.